SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollmentPliant’s proprietary selective, targeted, integrin-mediated delivery platformdemonstrates encouraging initial preclinical resultsStrengthened leadership team with appointments of David Raben, M.D., as Chief Med…

PLRX

Related stories